InMed Pharmaceuticals Inc. (INM) Latest Filing Signal

Latest Filing: 10-Q  |  Filed Feb 11, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for InMed Pharmaceuticals Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-Q, InMed Pharmaceuticals Inc.'s filing signal turned negative.
earningsVibe SuperAnalyst™ Verdict: TURNED NEGATIVE

Signal Performance — Stock Price Since Filing

30-Day Change
-22.12%
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Turned Negative
CLAUDE
Turned Negative
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does InMed Pharmaceuticals Inc. actually do?
Answer:
InMed Pharmaceuticals Inc. is a pharmaceutical drug development company focused on creating proprietary small molecule drug candidates that target the endocannabinoid system, specifically CB1 and CB2 receptors, for diseases with high unmet medical needs. The company is developing three lead drug candidates: INM-901 for Alzheimer's disease, INM-089 for dry Age-Related Macular Degeneration (AMD), and INM-755 for Epidermolysis Bullosa (EB). In addition to its pharmaceutical pipeline, InMed, through its subsidiary BayMedica, LLC, also develops and commercializes rare cannabinoids as ingredients for the health and wellness sector, utilizing various manufacturing approaches including chemical synthesis and biosynthesis.
Question:
What are InMed Pharmaceuticals Inc.'s revenue drivers?
Answer:
Revenue is generated from the manufacturing and distribution of bulk rare cannabinoids for the health and wellness sector through its BayMedica subsidiary. The company anticipates future revenue from its pharmaceutical drug candidates upon successful development and regulatory approval.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required